劉怡旻教授

Journal│Patent│

 

劉怡旻 教授    辦公室：U713    分機：2713    

   學歷：

  1. 國立成功大學醫學院，基礎醫學研究所，博士
  2. 中國醫藥學院，藥學系，學士
校內現職：
  1. 大仁科技大學 藥學系 教授
  2. 大仁科技大學 藥學系 系主任兼所長
  3. 大仁科技大學 藥學暨健康學院 院長

校內經歷：
  1. 大仁科技大學 藥學系 副教授
  2. 大仁技術學院 藥學系 助理教授
  3. 大仁科技大學 研究暨國際兩岸事務處 研發長

校外經歷：
  1. 衛生福利部中華藥典編修委員
  2. 衛生福利部臺灣中藥典編修委員
  3. 台灣藥學會理事
  4. 屏東縣衛生局藥師懲戒委員會委員
  5. 高雄市衛生局藥師懲戒委員會委員

Email：

教授科目：藥理學、藥物治療學、中藥藥理學

教研究主題：

  1.以胰島素抗性動物(細胞)模式為平台研究中草藥及衍生物對代謝症候群之調控機制

   (1) 胰島素抗性與腸道菌相: 探討特定中草藥或其純化物是否可透過調整腸道菌相改善胰島素敏 感性與葡萄糖代謝。

   (2) 中草藥對脂肪組織異常的影響: 分析是否能改善脂肪細胞肥大、抑制炎症細胞因子的釋放。

   (3) 胰島素抗性與肝臟脂肪變性的連結: 研究中草藥或其衍生物是否能透過 AMPK、PPAR 等路徑改善脂肪酸氧化，減少脂肪肝進展。

   (4) 腦部胰島素訊號與代謝症候群神經併發症: 探討特定純化物是否能改善胰島素抗性所引起的中樞神經系統病變。

   (5) 化學合成衍生物的結構與活性關係: 對比天然物與衍生物在葡萄糖攝取、胰島素受體磷酸化上的差異。

 2. 傳統中藥方劑與天然活性成分對糖尿病腎臟病變之藥效與安全性評估

   (1) 中藥方劑與天然活性成分對糖尿病腎臟病變的多靶點作用: 探討抗氧化、抗纖維化 (如TGF-β/Smad 路徑) 與抑制腎小球肥厚的綜合效應。

   (2) 中西藥合併之藥物交互作用：評估中藥方劑或是天然活性成分與常用降糖藥物（如SGLT2 inhibitors、DPP-4 inhibitors、GLP-1 agonists等）併用時的藥效與安全性影響。

  (3)腎臟毒性與安全性評估：系統性分析中藥方劑或天然活性成分中可能導致腎毒性的成分，並建立相關毒理學監測指標。
 

 

 Journal Papers

  1.  Lai MC, Liu WY, Tzeng YC, Liu IM* (2025 Sep). Protective Effects of Coixol Against Nε-Carboxymethyllysine-Induced Injury in IMR-32 Neuronal Cells: Modulation of Endoplasmic Reticulum Stress and Amyloidogenic Pathways. Nutrients, 17(18):2939. *本人為通訊作者.
  2. Liu YS, Lai MC, Hong TY, Liu IM* (2025 Feb).γ-Oryzanol: A nutrient-rich ingredient for promoting wound healing. Heliyon, 11(4):e42551. *本人為通訊作者.
  3. Liu YS, Lai MC, Tzeng YC, Liu IM* (2025 Jan). Polyphenolic Hispolon Derived from Medicinal Mushrooms of the Inonotus and Phellinus Genera Promotes Wound Healing in Hyperglycemia-Induced Impairments. Nutrients, 17(2):266. *本人為通訊作者.
  4. Jean SS, Ko WC, Liu IM, Hsieh PC, Hsueh PR (2024 Dec). Geographic differences in susceptibility profiles of potential non-class B carbapenemase-producing Enterobacterales isolates against ceftazidime-avibactam, meropenem-vaborbactam, colistin, amikacin, gentamicin, and tigecycline: Data from the antimicrobial testing leadership and surveillance, 2018-2022. International Journal of Antimicrobial Agents, 64(6), 107363.
  5. Jean SS, Liu CY, Huang TY, Lai CC, Liu IM, Hsieh PC, Hsueh PR (2024 Dec). Potentially effective antimicrobial treatment for pneumonia caused by isolates of carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii complex species: what can we expect in the future? Expert Review of Anti-infective Therapy, 22(12), 1171-1187.
  6. Kuo LK, Chang HT, Hsueh SC, Liu IM, Hsieh PC, Jean SS (2024 Oct). Bacterial profile, and independent predictors for healthcare-associated pneumonia persistently caused by multidrug-resistant Gram-negative bacteria for patients with the preceding multidrug-resistant Gram-negative pneumonia in Taiwan. Journal of Microbiology, Immunology, and Infection, 57(5), 801-811.
  7. Liu YS, Lai MC, Hong TY, Liu IM* (2024 Sep). Exploring the Wound Healing Potential of Hispidin. Nutrients,16(18), 3161. *本人為通訊作者.
  8. Chen LC, Lai MC, Hong TY, Liu IM* (2024 Apr). γ-Oryzanol from Rice Bran Antagonizes Glutamate-Induced Excitotoxicity in an In Vitro Model of Differentiated HT-22 Cells. Nutrients, 16(8), 1237. *本人為通訊作者.
  9. Hsueh SC, Huang YT, Ko WC, Liu IM, Hsieh PC, Jean SS (2024 Mar). In vitro antimicrobial susceptibility data of global meropenem-resistant Acinetobacter baumannii isolates causing pneumonia: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2014-2021, and re-estimations of susceptibility breakpoints and appropriate dosages of important antibiotics for pneumonia treatment. Journal of Global Antimicrobial Resistance, 36, 411-418.
  10. Jean SS, Liu CY, Huang YT, Ko WC, Ho MW, Liu IM, Hsieh PC, Hsueh PR (2024 Mar). Minimum inhibitory concentrations of antifungals against invasive isolates of Cryptococcus species worldwide: Global antifungal antimicrobial testing leadership and surveillance program, 2010-2020. International Journal of Antimicrobial Agents, 63(3), 107090.
  11. Li Y, Cheng KC, Liu IM, Cheng JT (2023 Oct). Identification of andrographolide as an agonist of bile acid TGR5 receptor in a cell line to demonstrate the reduction in hyperglycemia in Type-1 diabetic rats. Pharmaceuticals (Basel),16(10), 1417.
  12. Hsueh PR, Ho SJ, Hsieh PC, Liu IM, Jean SS (2023 Aug). Use of multiple doses of intravenous infusion of umbilical cord-mesenchymal stem cells for the treatment of adult patients with severe COVID-19-related acute respiratory distress syndrome: literature review. Stem Cells International, 2023, 7179592.
  13. Jean SS, Liu IM, Hsieh PC, Kuo DH, Liu YL, Hsueh PR (2023 May). Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria. International Journal of Antimicrobial Agents, 61(5), 106763.
  14. Lai MC, Liu WY, Liou SS, Liu IM* (2023 Jan). Hispidin in the medicinal fungus protects dopaminergic neurons from JNK activation-regulated mitochondrial-dependent apoptosis in an MPP+-induced in vitro model of Parkinson's disease. Nutrients, 15(3), 549. *本人為通訊作者.
  15. Cheng JT, Liu IM, Shen SC (2022 Oct). Plant therapeutics. Plants (Basel), 11(20):2720.
  16. Lai MC, Liu WY, Liou SS, Liu IM* (2022 Nov). p-Hydroxybenzyl alcohol antagonized the ROS-dependent JNK/Jun/Caspase-3 pathway to produce neuroprotection in a cellular model of Parkinson's disease. Nutrients, 14(23), 5002. *本人為通訊作者.
  17. Lai MC, Liu WY, Liou SS, Liu IM* (2022 May). Diosmetin targeted at peroxisome proliferator-activated receptor gamma alleviates advanced glycation end products induced neuronal injury. Nutrients, 14(11), 2248. *本人為通訊作者.
  18. Lai MC, Liu WY, Liou SS, Liu IM* (2022 Feb). The citrus flavonoid hesperetin encounters diabetes-mediated Alzheimer-type neuropathologic changes through relieving advanced glycation end-products inducing endoplasmic reticulum stress. Nutrients, 14(4):745. *本人為通訊作者.
  19. Li YX, Cheng KC, Liu IM, Niu HS* (2022 Jan) Myricetin increases circulating adropin level after activation of glucagon-like peptide 1 (GLP-1) receptor in type-1 diabetic rats. Pharmaceuticals (Basel),15,173.

Patent

  1. 劉怡旻;張家茹;劉崇喜，“A ginger extract for inhibiting the fat-storage funvtion of adipocytes”， 美國發明專利，已核准證書字號：US 8,501,249 B2
  2. 劉崇喜;劉怡旻;張家茹;唐偉智，“Herbal preparation for anemia and a manufacture method thereof”， 美國發明專利，已核准證書字號：US 8,420,136 B2
  3. 劉崇喜;劉怡旻;李瑞瑜，『從山藥塊根外皮萃取抗氧化物質之製備方法』，中華民國發明專利，已核准證書字號：I379687，2012.12.21 ~ 2029.9.8。
  4. 劉怡旻;劉崇喜;張家茹，『薄荷抗氧化物質之恆溫萃取法』，中華民國發明專利，已核准證書字號：I361097，2012.4.1~2029.8.30。
  5. 劉崇喜;劉怡旻，『中藥當歸之定量定溫及定時炮製法』，中華民國發明專利，已核准證書字號：I339123，2011.3.21~2027.9.6。
 

 TOP